Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals
Somatostatin receptors (SSTs) are recognized as favorable molecular targets in neuroendocrine tumors (NETs) and neuroendocrine neoplasms (NENs), with subtype 2 (SST<sub>2</sub>) being the predominantly and most frequently expressed. PET/CT imaging with <sup>68</sup>Ga-labeled...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/5/1172 |